Biological function of CD109 in hematopoiesis.

2020 Fiscal Year Final Research Report

• Project/Area Number: 18K08371
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 54010:Hematology and medical oncology-related
• Research Institution: Kitasato University
• Principal Investigator: Suzuki Takahiro 北里大学, 医学部, 教授 (40345210)
• Project Period (FY): 2018-04-01 – 2021-03-31
• Keywords: CD109 / 造血分化

Outline of Final Research Achievements

CD109 is a negative regulator for TGFb which is a key regulatory molecule for hematopoiesis and oncogenesis. In the research, we analyzed biological function of CD109 using knockout mice. We found that CD109 was expressed in mature B cells, and in the knockout mice, plasmablasts in the spleen showed tendency of decrease. Of note, expression of CD109 was not observed in the murine bone marrow cells, which was a major difference between human and mice. We also analyzed the value of serum soluble CD109 in healthy volunteers and patients with hematological disorders. The result showed that soluble CD109 had a tendency of increase in patients with immune thrombocytopenia (ITP), and soluble CD109 may be useful for the diagnosis and clinical follow-up for ITP.

Free Research Field

血液内科学

Academic Significance and Societal Importance of the Research Achievements

本研究は、造血器腫瘍・骨髄造血の制御因子であるTGFb分子に関わる研究であり、CD109分子についてマウス・ヒトにおける発現が明らかとなった。マウスにおいては骨髄細胞でCD109の発現が認められないことが明確となり、マウスで研究を行う場合には注意が必要であることが判明した。また、ヒト疾患との関連については、血清可溶性CD109の健常人における値が明らかになるとともに、免疫性血小板減少症で可溶性CD109が高値傾向になり、鑑別診断や病態把握に有用である可能性が明らかとなった。